The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1336
April 19, 2010
View Complete Issue         Table of Contents 2019 
Dutasteride (Avodart) for Prevention of Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dutasteride (Avodart) for Prevention of Prostate Cancer
April 19, 2010 (Issue: 1336)
A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart – GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic hyperplasia, reduced the risk of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dutasteride (Avodart) for Prevention of Prostate Cancer
Article code: 1336a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.